Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

The FNIH Biomarkers Consortium embraces the BEST

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Nature Reviews Drug Discovery 18, 567-568 (2019)

doi: https://doi.org/10.1038/d41573-019-00015-w

Acknowledgements

The authors acknowledge the contribution of J. Altshuler and S. Staats from Altshuler and Staats for their work on the strategic analysis, as well as the support and feedback from the members of the Biomarkers Consortium executive committee, particularly P. Herrling, chair of the executive committee and FNIH board member.

References

  1. Powers, J. H. et al. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin. Infect. Dis. 63, S52–S56 (2016).

    PubMed  Article  Google Scholar 

  2. Carey, L. A. & Winer, E. P. I-SPY 2–Toward more rapid progress in breast cancer treatment. N. Engl. J. Med. 375, 83–84 (2016).

    PubMed  Article  Google Scholar 

  3. Leptak, C. et al. What evidence do we need for biomarker qualification? Sci. Transl Med. 9, eaal4599 (2017)

    PubMed  Article  Google Scholar 

Download references

Competing Interests

J.A.W. is an employee of Takeda Pharmaceuticals. J.P.M., C.A., L.S.B., G.E., C.L. and A.M. declare no conflicts.

Subjects

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links